<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492178</url>
  </required_header>
  <id_info>
    <org_study_id>REACH</org_study_id>
    <nct_id>NCT02492178</nct_id>
  </id_info>
  <brief_title>Bio-availability of Rectal Artesunate in Children With Severe Falciparum Malaria</brief_title>
  <acronym>REACH</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kinshasa School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at describing the pharmacokinetic properties of rectal artesunate in well
      characterized severely ill patients using intravenous artesunate as a comparator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individually randomized, open label, 2-arm, cross-over, clinical trial. Patients are
      allocated to receive rectal artesunate at admission and intravenous artesunate after 12 hours
      or intravenous artesunate at admission and rectal artesunate after 12 hours. All patients are
      treated for severe malaria with intravenous quinine. Frequent blood samples are taken at
      fixed intervals after the administration of the first and the second dose of study drug. The
      time frame is 24 hours and thereafter patients continue the standard antimalarial therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics profile of rectal artesunate</measure>
    <time_frame>24 hours</time_frame>
    <description>The pharmacokinetics profile of rectal artesunate (the study drug), consisting of: area under the concentration-time curve; terminal elimination half-life; elimination clearance; apparent volume of distribution will be measured and compared to the pharmacokinetic profile of intravenous artesunate (the comparator).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>IR artesunate + IV artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV artesunate + IR artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrarectal artesunate</intervention_name>
    <arm_group_label>IR artesunate + IV artesunate</arm_group_label>
    <arm_group_label>IV artesunate + IR artesunate</arm_group_label>
    <other_name>artesunate suppositories</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous artesunate</intervention_name>
    <arm_group_label>IR artesunate + IV artesunate</arm_group_label>
    <arm_group_label>IV artesunate + IR artesunate</arm_group_label>
    <other_name>parenteral artesunate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous quinine</intervention_name>
    <arm_group_label>IR artesunate + IV artesunate</arm_group_label>
    <arm_group_label>IV artesunate + IR artesunate</arm_group_label>
    <other_name>parenteral quinine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight ≥6 kilograms and ≤ 34 kilograms

          -  Severe malaria (WHO Guidelines 2013; Appendix 1)

          -  P. falciparum infection confirmed by Rapid Diagnostic Test (P. falciparum
             monoinfection or mixed infection with P. ovale or P. malariae)

          -  Parents or guardian signed Informed Consent

        Exclusion Criteria:

          -  Acute diarrhoea defined as &gt; 3 liquid stools in the previous 24 hours

          -  Visible anorectal malformations or a disease of the rectum

          -  Known hypersensitivity to quinine or artesunate

          -  A documented history of an effective dose of parenteral antimalarial in the preceding
             24 hours or a single dose of rectal artesunate in the previous 12 hours or a dose of
             an artemisinin based combination therapy in the previous 6 hours

          -  Co-morbidity which in the judgement of the investigator would interfere with the
             patient treatment or results of the study or place the subject at undue risk

          -  Participation in another clinical trial or earlier in the same clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kinshasa School of Public Health</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Quinine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

